PARAMUS, N.J., Sept. 19, 2025 /PRNewswire/ -- NS Pharma, Inc. announced today that the U.S. Food & Drug Administration (FDA) has granted Orphan Drug Designation to NS-051/NCNP-04 which is being developed for the treatment of Duchenne muscular dystrophy (Duchenne) in patients amenable to...
Hence then, the article about fda grants orphan drug designation to ns 051 ncnp 04 for the treatment of duchenne muscular dystrophy was published today ( ) and is available on PR Newswire ( Middle East ) The editorial team at PressBee has edited and verified it, and it may have been modified, fully republished, or quoted. You can read and follow the updates of this news or article from its original source.
Read More Details
Finally We wish PressBee provided you with enough information of ( FDA Grants Orphan Drug Designation to NS-051/NCNP-04 for the Treatment of Duchenne Muscular Dystrophy )
Also on site :
- Big wind ambition, real infrastructure gap: Ireland must accelerate now
- Trump’s Renewed Iran Threats Drive Oil Higher
- Quest Global wird im ISG Provider Lens®-Bericht 2025 als führender Anbieter von Dienstleistungen und Lösungen für die Fertigungsindustrie ausgezeichnet